Latest news with #CentralNervousSystem
The Hindu
10 hours ago
- Health
- The Hindu
When seizures take over your life – the story of a 12-year-old boy battling multiple seizures
A 12-year-old boy from Yemen, named Yusuf, was suffering from multiple seizures every single day for a very long time. He was placed on 7 to 8 anti-epileptic medicines and was unable to walk, go to school, and even do simple tasks without help. His childhood was slowly slipping away, not just to a disease, but to the fear and helplessness that comes with it. An MRI scan done in his country showed a lesion on left side of brain, which had been previously ignored as a scar. Further investigations were conducted, including a battery of tests like video EEG, special MRIs including functional MRI, and interictal PET scans, after which it was found that the lesion in his brain was actually a tumour, and his seizures were originating from it. A precise yet gentle procedure known as a craniectomy with neuro-navigation guided microscopic tumour removal was performed — not just to remove the tumour, but to give Yusuf a chance at a normal, seizure-free life. Biopsy of the tumour tissue showed that the lesion on the left side of the brain was in fact a Dysembryoplastic Neuroepithelial Tumor (DNET), a rare, benign brain tumour commonly associated with drug-resistant epilepsy in children. Only three weeks post-operation, Yusuf had eliminated seizures. With full restoration of physical abilities, he was able to walk, run, and return to school, allowing him to fully embrace the joys of childhood without fear. A seizure is one of the most terrifying experiences one may have It starts with subtle neurological signs of sudden blackouts, a strange twitching while watching TV, or a moment of lost time during your morning commute. For many, these instances are ignored, thinking of as stress or dehydration, but these can be the early signs of seizures. Seizures are among the most common neurological symptoms, which relate to epilepsy, a chronic disorder that involves abnormal brain activity that results in recurrent seizures. However, not every seizure is caused by epilepsy. When this frequently occurs, it may be a sign of a brain tumour. Brain tumour is an abnormal growth of tissue within the brain and Central Nervous System (CNS) that can disrupt the normal functioning of the brain. These tumours can be either benign (non-cancerous) or malignant (cancerous). They may originate in the brain itself or spread from other parts of the body. As per the GLOBOCAN 2022, brain tumours in India account for around 2% of all cancer-related cases in India, with new patients crossing the 30,000 mark annually. Children's brain tumours are particularly concerning, with the increase in diagnoses emphasising the importance of awareness and accessibility to specialised treatment needed during the early stage. Recognising the signs Brain tumours can show their symptoms in many ways, depending on their location and growth. Warning signs include persistent morning headaches, frequent nausea, new or worsening seizures, vision or hearing changes, movement difficulties, memory loss, personality shifts, and, in children, delays in milestones like walking. While all symptoms need immediate attention, seizures and sudden behaviour changes should never be ignored. Seizures in epilepsy follow a consistent pattern and are often the only symptom of this condition. Whereas in the case of a brain tumour, seizures are accompanied by a variety of symptoms such as speech difficulties, vision problems, and other cognitive and behavioural alterations. Seizures are usually connected with epilepsy, a chronic disorder characterised by recurring episodes of abnormal brain activity and can signal a brain tumour as well as this triggers the surrounding brain tissue, disrupting normal electrical activity, leading to seizures. Brain tumours can affect anyone however, the impact is most pronounced in children. Even non-cancerous tumours can have a significant impact on the functions of the brain. Children diagnosed with brain tumours often suffer from epilepsy that does not respond to medication, causing intellectual stagnation, impairments in physical abilities, and acquired dependence. Besides the physical dangers posed, seizures are perhaps the most traumatic symptom and necessitate great mental strength from both the child and their loved ones. A unique but significant tumour to be familiar with is the Dysembryoplastic Neuroepithelial Tumor (DNET). This tumour is often associated with medically refractory epilepsy in children, and if left undiagnosed and untreated, it can greatly diminish their quality of life. Safeguarding ourselves and our family members It is important to recognise that many brain tumours develop due to complex genetic and environmental factors beyond our control. While not all brain tumours are preventable, certain lifestyle habits may help reduce the risk. Minimising unnecessary radiation exposure, using a hands-free mobile phone, and avoiding harmful substances such as tobacco can all help. Maintaining a healthy lifestyle, which includes regular exercise, a balanced diet, and adequate sleep, also benefits brain health. Most importantly, being aware of early warning symptoms such as persistent headaches or personality changes and getting instant medical assistance can result in early detection and better outcomes. In the case of unexplained seizure episodes or any other concerning symptoms, consultation with the doctor should be done without any delay, as timely intervention and focused action on the problem can be life changing. (Dr. Anurag Saxena,Cluster Head Delhi NCR – Department of Neurosurgery, Manipal Hospital Dwarka, New Delhi, Email :
Business Wire
13-05-2025
- Business
- Business Wire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the 'Company' or 'Anebulo'), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced Central Nervous System ('CNS') depression. The Company plans to begin dosing healthy adult volunteers in its Phase 1 single ascending dose ('SAD') study of intravenous selonabant in the third quarter of calendar 2025. 'We anticipate initiating our Phase 1 SAD study of intravenous selonabant in healthy adults aged 18 to 25 years in the third quarter of calendar 2025,' commented Richie Cunningham, Chief Executive Officer of Anebulo. Cunningham continued, 'There is a significant and growing unmet medical need for an emergency antidote to acute cannabis-induced toxicity. In particular, acute cannabis exposure in children can result in serious and potentially life-threatening consequences, including CNS depression, respiratory depression, coma, and in rare cases death. Research has shown that children are much more sensitive to the toxic effects of cannabis, due in part to age-related differences in the abundance and distribution of cannabis receptors in their brains. As a consequence, cannabis ingestion in children can result in much more serious outcomes than in adults, and a much greater risk of hospitalization and admission to intensive care. In a pre-Investigational New Drug ('IND') application interaction, Food and Drug Administration confirmed our belief that there is an unmet need for a treatment for children exposed to cannabis toxicity and suggested a close collaboration with Anebulo to facilitate an efficient development plan for this important pediatric condition. If approved, we believe selonabant has the potential to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children.' Financial Results for the three months ended March 31, 2025 Operating expenses in the third quarter of fiscal 2025 were $1.9 million compared with $1.7 million in the same period in fiscal 2024. Net loss in the third quarter of fiscal 2025 was $1.7 million, or $(0.04) per share, compared with a net loss of $1.7 million, or $(0.06) per share, in the third quarter of fiscal 2024. Cash and cash equivalents were $13.3 million as of March 31, 2025. The Company also has access to an additional $3 million in cash through a Loan Agreement. About Selonabant The Company's lead product candidate is selonabant (ANEB-001), a potent, small molecule antagonist of the cannabinoid receptor type-1 ('CB1'), under development to address the unmet medical need for a specific antidote for acute cannabis-induced toxicity, including acute cannabinoid intoxication ('ACI') in adults and cannabis poisoning in pediatric subjects. The Company anticipates that selonabant will rapidly reverse key symptoms of acute cannabis-induced toxicity. Selonabant has been successfully formulated for oral administration in clinical studies and as a potential intravenous treatment for clinical testing. In a Phase 2 proof-of-concept study in adult subjects challenged with oral delta-9-tetrahydrocannabinol ('THC') ( oral selonabant blocked or reversed key CNS effects of THC. Selonabant was well tolerated in this study and there were no serious adverse events. In the open-label extension of the study, THC challenge doses of 40 mg and 60 mg were well-tolerated when dosed in combination with oral selonabant, and all treatment-related adverse events were mild and transient. The prior Phase 1 and Phase 2 studies of oral selonabant have together enrolled a total of 250 subjects, of which 191 received selonabant. Selonabant is protected by two issued patents covering various methods of use of the compound and composition of matter of the crystalline form of selonabant. Anebulo also has multiple pending applications covering various methods of use of the compound and delivery systems. An observational study in patients presenting to Emergency Departments with cannabis toxicity is currently ongoing and is being amended to focus on pediatric patients. The study is intended to determine concentrations of cannabinoids and metabolites in plasma and gather information on signs and symptoms, treatment, and patient disposition, including hospital/ICU admission. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel solutions for people suffering from cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. Rather than proceeding directly with Phase 3 studies of oral selonabant in adults with ACI, the Company is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product. Anebulo is currently scaling up the intravenous formulation for initial clinical safety studies. Selonabant is a competitive antagonist at the human CB1 receptor. For further information about Anebulo, please visit Forward-Looking Statements Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as 'anticipate,' 'designed,' 'expect,' 'may,' 'will,' 'should' and other comparable terms. Forward-looking statements include statements regarding Anebulo's intentions, beliefs, projections, outlook, analyses or current expectations regarding: intravenous selonabant as a potential treatment for pediatric patients with cannabis-induced CNS depression; initiating its Phase 1 SAD study of intravenous selonabant in healthy adults aged 18 to 25 years in the third quarter of calendar 2025; the belief that there is an unmet need for a treatment for children exposed to cannabis toxicity; selonabant having the potential to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children; selonabant rapidly reversing key symptoms of cannabis toxicity; the observational study determining concentrations of cannabinoids and metabolites in plasma and gathering information on signs and symptoms, patients' disposition and selected subjective assessments; and a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, offering the potential for a faster timeline to approval relative to the adult oral product. You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: Anebulo's ability to pursue its regulatory strategy including the initiation of its Phase 1 SAD study of intravenous selonabant in healthy adults aged 18 to 25 years in the third quarter of calendar 2025; the ability of selonabant to be a potential treatment for pediatric patients with cannabis-induced CNS depression; the ability of selonabant to rapidly reverse key symptoms of cannabis toxicity, including acute cannabis-induced toxicity in children; the ability of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, offering the potential for a faster timeline to approval relative to the adult oral product; Anebulo's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, Anebulo's ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of Anebulo's products, Anebulo's ability to maintain its license agreements, the continued maintenance and growth of its patent estate and Anebulo's ability to retain its key employees or maintain its Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in Anebulo's Annual Report on Form 10-K for the year ended June 30, 2024, and its subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release. Condensed Statements of Operations Three months ended March 31, 2025 2024 Research and development $ 638,324 $ 748,339 General and administrative 1,253,998 915,912 Total operating expenses 1,892,322 1,664,251 Loss from operations (1,892,322 ) (1,664,251 ) Other (income) expenses: Interest expense 245,182 59,696 Interest income (102,257 ) (68,084 ) Grant income (359,606 ) - Other 528 (2,321 ) Total other income, net (216,153 ) (10,709 ) Net loss $ (1,676,169 ) $ (1,653,542 ) Weighted average common shares outstanding, basic and diluted 41,084,731 25,933,217 Net loss per share, basic and diluted $ (0.04 ) $ (0.06 ) Expand
Yahoo
21-03-2025
- Yahoo
Man injured in deadly I-35 crash files $100 million civil lawsuit against driver, Amazon, ZBN Transport
AUSTIN (KXAN) — A man seriously injured in a crash on I-35 that killed five people earlier this month has filed a $100 million civil lawsuit against Amazon, a trucking company and the driver who police say caused the crash. Nathan Jonard filed suit against Amazon Logistics, ZBN Transport and Solomun Weldekeal-Araya in Travis County Thursday. Five people were killed and 11 others injured, including Jonard, in the March 13 crash, which happed on I-35 near Parmer Lane and Howard Lane. The crash involved 18 vehicles, including a box truck, two truck tractors, two semi-trailers and 13 passenger cars, according to an arrest affidavit for Weldekeal-Araya. Weldekeal-Araya was arrested and charged with five counts of intoxication manslaughter with a vehicle and two counts of intoxication assault with vehicle involving serious bodily injury. In the arrest affidavit, investigators said they believe he 'was under the influence of Central Nervous System (CNS) depressants and was unable to operate a motor vehicle safely.' 'Nathan Jonard was simply trying to make it home to his family,' the lawsuit said. 'Before he could, his life was forever changed by an act of unimaginable destruction.' The lawsuit claims Jonard came to a stop in traffic due to construction, but that Weldekeal-Araya 'failed to slow down or stop, resulting in a high-impact, high-speed collision.' Previous coverage: 'It was hard to see this': Bystanders help after fatal 17-vehicle crash Jonard suffered multiple broken ribs and other bones. He also had a dissected artery in his neck which required surgery, according to the lawsuit, as well as a herniated disc, deep lacerations to his body and 'particularly gruesome wounds' on his head, legs and feet. Weldekeal-Araya, 37, was driving a semi truck for Amazon at the time of the crash, but the crash was owned by ZBN Transport LLC. He was not an Amazon employee. 'This is a horrible tragedy, and our thoughts are with all those involved,' Amazon spokesperson Amber Plunkett told KXAN after the crash. 'We're looking into this further and will cooperate with law enforcement as they investigate.' ZBN Transport told KXAN Weldekeal-Araya had been with the company for about four months, and there have not been any prior issues with him. Additionally, the company said it conducts background checks, and nothing showed up for Weldekeal-Araya. KXAN has reached out to both Amazon and ZBN Transport, as well as Weldekeal-Araya's attorney for comment on the new lawsuit. '[ZBN and/or Amazon] failed to exercise the requisite care, skill and expertise as would an ordinary person when hiring, retaining, entrusting a vehicle to, and training (or rather not training' [Weldekeal-Araya],' the lawsuit said.' Jonard is seeking 'monetary relief in excess of $100 million,' in part to cover medical bills, lost wages and lost property, as well as compensation for pain, suffering, mental anguish, physical disfigurement and impairment. Three of the five victims were identified by Austin police on Tuesday. Sergieo Daniel Lopez, 32, and Natalia Helana Perez, 25, along with Ma Concepcion Joaquin De Joaquin, 78, were killed in the crash, along with two juveniles who have not yet been named. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
